Human CD16a (158F) (Luc) Jurkat Reporter Cell

• Genetically modified cell lines best reflect MOA (Mechanism of Action)
• Higher activity and larger assay window for robust and reproducible cell-based bioassay
• Comprehensive application data to support assay development and validation
• Full tracible record, stringent quality control and validated cell passage stability
• Parental cell line legally obtained from internationally recognized cell resource bank and commercially licensed
• Global commercial license assistance whenever regulatory filing is required

The Human CD16a (158F) (Luc) Jurkat Reporter Cell was engineered to not only express the NFAT response element driving luciferase expressing systems, but also express the receptor full length human CD16a (158F) (Uniprot: P08637) exhibiting a lower affinity for IgG1 and IgG3 isotypes compared to CD16a-158V, which can use to evaluate ADCC activity of antibodies in the presence of corresponding target cells. When co-cultured with a target cell and relevant antibody, the antibody simultaneously binds the target cell antigen and CD16a (158F) receptor on the surface of Human CD16a (Luc) (158F) Jurkat Reporter Cell, resulting in receptor clustering, intracellular signaling and NFAT-mediated luminescence.

• Determination of ADCC activity induced by antibodies.

Suspension

Puromycin (5 μg/mL) + Hygromycin B (20 μg/mL)

RPMI-1640 + 10% FBS

Serum-free cell cryopreservation medium

1 vial contains at least 5×10^6 cells in 1 mL serum-free cryopreservation medium

Frozen in liquid nitrogen.

Negative

Negative

See data sheet for detailed culturing and assay protocol.